Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levobupivacaine Infiltration Prior to Surgery for Triple-Negative Breast Cancer
NCT07458204Phase 2Not yet recruiting
- Sponsor
- Institut Godinot
- Start
- Oct 2026
- Primary completion
- Oct 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of levobupivacaine in triple-negative breast cancer (TNBC), sponsored by Institut Godinot. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
levobupivacaine
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07458204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07458204.